Phase II Study of Pembrolizumab and Itacitinib for First Line Treatment of Metastatic NSCLC Expressing PD-L1

被引：0
|
作者：
Marmarelis, M. E. [1 ]
Mathew, D. [1 ]
Bauml, J. M. [2 ]
Hwang, W. -T. [1 ]
Zhang, J. [1 ]
Singh, A. [1 ]
D'Avella, C. [1 ]
Davis, C. [1 ]
Ye, D. [1 ]
Sun, L. [1 ]
Ciunci, C. [1 ]
Zhang, N. [1 ]
Aggarwal, C. [1 ]
Cohen, R. B. [1 ]
Minn, A. J. [1 ]
Wherry, E. J. [1 ]
Langer, C. J. [1 ]
机构：
[1] Univ Penn, Philadelphia, PA 19104 USA
[2] Janssen, Philadelphia, PA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
Immunotherapy; JAK; pembrolizumab;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.15-07
引用
收藏
页码：S122 / S123
页数：2
相关论文
共 50 条
  • [1] Phase II Study of Pembrolizumab and Itacitinib for Patients with Metastatic NSCLC Expressing PD-L1: Long-Term Follow up
    Marmarelis, M. E.
    Cantor, D. J.
    Mathew, D.
    McWilliams, T.
    Bauml, J.
    Hwang, W-T
    Singh, A.
    D'Avella, C.
    Davis, C.
    Ye, D.
    Sun, L.
    Ciunci, C.
    Aggarwal, C.
    Cohen, R. B.
    Minn, A.
    Wherry, J.
    Langer, C. J.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S20 - S20
  • [2] The effect of tumor size and metastatic extent on the efficacy of first line pembrolizumab monotherapy in patients with high PD-L1 expressing advanced NSCLC tumors
    Schakenraad, Alexandra
    Hashemi, Sayed
    Twisk, Jos
    Houda, Ilias
    Ulas, Ezgi
    Daniels, Johannes M. A.
    Veltman, Joris
    Bahce, I.
    LUNG CANCER, 2021, 162 : 36 - 41
  • [3] Phase III Trial of Pembrolizumab-Chemotherapy Versus Pembrolizumab in First-Line of Advanced NSCLC with PD-L1 ≥50%: PERSEE
    Descourt, R.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1011 - S1011
  • [4] New drug approval: Pembrolizumab in association with chemotherapy as first line treatment for advanced/metastatic oesophageal carcinomas or HERnegative gastroesophageal adenocarcinoma, expressing PD-L1 with a CPS ≥ 10
    Quesada, Stanislas
    Vaflard, Pauline
    BULLETIN DU CANCER, 2022, 109 (02) : 111 - 113
  • [5] Prognostic value of the Scottish Inflammatory prognostic Score in patients with NSCLC expressing PD-L1 ≥ 50 % progressing on first-line pembrolizumab
    Stares, Mark
    Doyle, Emma
    Chapple, Sally
    Raynes, George
    MacDonald, James
    Barrie, Colin
    Laird, Barry
    MacKean, Melanie
    Philips, Iain
    LUNG CANCER, 2024, 189
  • [6] Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC
    Wan, Ning
    Zhang, Tian-tian
    Hua, Si-hua
    Lu, Zi-luo
    Ji, Bo
    Li, Li-xia
    Lu, Li-qing
    Huang, Wen-jie
    Jiang, Jie
    Li, Jian
    CANCER MEDICINE, 2020, 9 (05): : 1683 - 1693
  • [7] Cost-Effectiveness of Pembrolizumab as 1st Line Treatment for Metastatic NSCLC Patients with High PD-L1 Expression in Singapore
    Tan, W. L.
    Huang, M.
    Chandwani, S.
    Hsu, T.
    Tan, S. C.
    Tan, D.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S630 - S630
  • [8] Phase 3 Study of First-Line Pembrolizumab ± Vibostolimab (anti-TIGIT) in Patients With PD-L1-Positive Metastatic NSCLC
    Hellmann, M. D.
    Cho, B. C.
    Juergens, R.
    Cheng, Y.
    De Castro, G., Jr.
    Erman, M.
    Bauman, J. R.
    Takahashi, T.
    Schwarzenberger, P.
    Zhang, P.
    Pietanza, M. C.
    Yang, J. C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1010 - S1011
  • [9] PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis
    Lo Russo, Giuseppe
    Prelaj, Arsela
    Dolezal, James
    Beninato, Teresa
    Agnelli, Luca
    Triulzi, Tiziana
    Fabbri, Alessandra
    Lorenzini, Daniele
    Ferrara, Roberto
    Brambilla, Marta
    Occhipinti, Mario
    Mazzeo, Laura
    Provenzano, Leonardo
    Spagnoletti, Andrea
    Viscardi, Giuseppe
    Sgambelluri, Francesco
    Brich, Silvia
    Miskovic, Vanja
    Pedrocchi, Alessandra Laura Giulia
    Trovo', Francesco
    Manglaviti, Sara
    Giani, Claudia
    Ambrosini, Paolo
    Leporati, Rita
    Franza, Andrea
    Mcculloch, John
    Torelli, Tommaso
    Anichini, Andrea
    Mortarini, Roberta
    Trinchieri, Giorgio
    Pruneri, Giancarlo
    Torri, Valter
    De Braud, Filippo
    Proto, Claudia
    Ganzinelli, Monica
    Garassino, Marina Chiara
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (06)
  • [10] PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers
    Lo Russo, G.
    Sgambelluri, F.
    Prelaj, A.
    Galli, F.
    Manglaviti, S.
    Bottiglieri, A.
    Di Mauro, R. M.
    Ferrara, R.
    Galli, G.
    Signorelli, D.
    De Toma, A.
    Occhipinti, M.
    Brambilla, M.
    Rulli, E.
    Triulzi, T.
    Torelli, T.
    Agnelli, L.
    Brich, S.
    Martinetti, A.
    Dumitrascu, A. D.
    Torri, V
    Pruneri, G.
    Fabbri, A.
    de Braud, F.
    Anichini, A.
    Proto, C.
    Ganzinelli, M.
    Mortarini, R.
    Garassino, M. C.
    ESMO OPEN, 2022, 7 (06)
12345